Brief: BCAL Diagnostics Submits MSAC Application For Avantect Pancreatic Cancer Early Detection Blood Test
31/03/2026 02:52
March 31 (Reuters) - BCAL Diagnostics Ltd BDX.AX: SUBMITS MSAC APPLICATION FOR AVANTECT PANCREATIC CANCER EARLY DETECTION BLOOD TEST Further company coverage: BDX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BCAL Diagnostics
See all newsAustralia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: BCAL Diagnostics Introduces Avantect Multi-Cancer Early Detection Test
Brief: BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: BCAL To Acquire Shares In Genetic Signatures